Q-omics provides the consensus-scored ZNF518B profile across patient tissues and cancer cell-line models. ZNF518B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF518B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ZNF518B RNA expression shows 20,649 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where ZNF518B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF518B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF518B survival associations across molecular data types. ZNF518B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF518B RNA expression–survival associations across cancer types. High ZNF518B expression shows unfavorable associations in LGG and UVM, but favorable associations in KIRC, UCS, ACC and STAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF518B RNA expression.
This table summarizes ZNF518B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF518B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF518B shows lower tumor expression in KIRC, KICH, THCA and COAD and higher tumor expression in LUSC and CHOL. The KIRC box plot shows higher ZNF518B RNA expression in normal versus tumor tissue (log2 FC = −0.773, t-test p < 0.001).
This table shows molecular features associated with ZNF518B in patient tissues and cancer cell lines. In patient samples, ZNF518B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF518B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
